Page 47 - Magyar Gasztroenterológiai Társaság 2020. november 6–7. – ONLINE KONGRESSZUS

Előadáskivonatok / Abstracts

(CI: 1.01—1.38), I =38.7%], while the risk of severe GI side
2
Introduction: Several factors may affect the rate of effects was not increased in this subgroup [RR=1.21 (CI:

(CI: 1.01—1.38), I =38.7%], while the risk of severe GI side
2
postoperative complications in patients with inflammatory 0.84—1.74, I =0.0%]. ased in this subgroup [RR=1.21 (CI:
effects was not incre
Introduction: Several factors may affect the rate of
2
postoperative complications in patients with inflammatory
0.84—1.74, I =0.0%].
2
bowel disease (IBD). Hypoalbuminemia and malnutrition are Conclusion: Our results show that bisphosphonates do not
bowel disease (IBD). Hypoalbuminemia and malnutrition are
Conclusion: Our results show that bisphosphonates do not
considered to be the most important ones. However, it is not increase the risk of severe GI adverse events, requiring
considered to be the most important ones. However, it is not
increase the risk of severe GI adverse events, requiring
revealed which body compartments deterioration may specialist care or endoscopy. However, alendronate is
specialist care or endoscopy. However, alendronate
influence the frequency of postoperative complications. may associated with an 18% increased risk of non-severe GI side is
revealed which body compartments deterioration
Aims: The aim of the study is to determine whether the effects.
influence the frequency of postoperative complications.
associated with an 18% increased risk of non-severe GI side
Aims: The aim of the study is to determine whether the
preoperative sarcopenia has an independent effect on the effects.

preoperative sarcopenia has an independent effect on the
frequency of postoperative complications. 34. CORRELATION BETWEEN FECAL INFLIXIMAB
AND
34. CORRELATIO
ACTIVITY
OBJECTIVE
Patients: Ulcerative colitis (UC) and Crohn’s disease (CD) CONCENTRATION N BETWEEN FECAL INFLIXIMAB
frequency of postoperative complications.
OBJECTIVE
Patients: Ulcerative colitis (UC) and Crohn’s disease (CD)
CONCENTRATION
AND
ACTIVITY
patients will be included. In case of UC patients with total MARKERS IN INFLAMMATORY BOWEL DISEASE
MARKERS
colectomy due to therapy resistance, malignancy or PATIENTS IN INFLAMMATORY BOWEL DISEASE
patients will be included. In case of UC patients with total
premalignancy will be involved. In case of CD, patients with Farkas K. , Szántó K. , Kata D. , Földesi I. , Ferenci T. ,
PATIENTS
colectomy due to therapy resistance, malignancy or
2
3
1
1
2
1
premalignancy will be involved. In case of CD, patients with
3
Farkas K. , Szántó K. , Kata D. , Földesi I. , Ferenci T.
2
2
1 1
1
1
1
plans of small bowel strictureplasty/resection, ileocoecal Rutka M. , Bor R. , Fábián A. , Resál T. , Nagy F. , Szepes ,
1
1
resection and/or segmental colon resection will be included. Z. , Molnár T. R. , Fábián A. , Resál T. , Nagy F. , Szepes
1
Rutka M. , Bor
1
plans of small bowel strictureplasty/resection, ileocoecal
1
1
1
1
resection and/or segmental colon resection will be included.
1
Number of needed patients will be determined by power 1. 1st Department of Medicine, University of Szeged; 2.
Z. , Molnár T.
1
Number
1. 1st Department of Medicine, University of Szeged; 2.
analysis. of needed patients will be determined by power Department of Laboratory Medicine, University of Szeged; 3.
Department of Laboratory Medicine, University of Szeged; 3.
Methods: Preoperative body composition is planned to Physiological Controls Research Center, Óbuda University
analysis.
Methods: Preoperative body composition is planned to
measure with bioimpedance method. Fat free mass, fat free Physiological Controls Research Center, Óbuda University

measure with bioimpedance method. Fat free mass, fat free
mass index, total body water, and lean muscle mass, body Introduction: Faecal drug concentration is not routinely
mass index, and nutritional status specific laboratory measured as per therapeutic drug monitoring strategies in
mass index, total body water, and lean muscle mass, body
Introduction: Faecal drug concentration is not routinely
measured as per therapeutic drug monitoring strategies
mass index, and nutritional status specific laboratory
parameters will be measured at the time of the indication and inflammatory bowel disease (IBD) patients receiving anti- in
3-5 day before the operation. Number of surgical site TNF therapy. However, our previous research work
inflammatory bowel disease (IBD) patients receiving anti-
parameters will be measured at the time of the indication and
infection, suture insufficiency, need for reoperation will be suggested the importance of faecal drug monitoring of anti
3-5 day before the operation. Number of surgical site
TNF therapy. However, our previous research work
suggested the importance of faecal drug monitoring of anti
infection, suture insufficiency, need for reoperation will be
determined at weeks 2, 6, 12, 26 and 52. Clinical relapse and TNF agents since active disease may be present in spite of
TNF agents since active disease may be present in spite of
determined at weeks 2, 6, 12, 26 and 52. Clinical relapse and
at inflammatory biomarkers will be registered in every three normal serum anti-TNF levels.
at inflammatory biomarkers will be registered in every three
normal serum anti-TNF levels.
months. Endoscopic relapse will be determined at month 6 Aims: The aim of the present study was to examine the
Aims: The aim of the present study was to examine the
and 12. Cut off levels of the preoperative measured correlation between faecal infliximab (IFX) concentration and
months. Endoscopic relapse will be determined at month 6
parameters will be determined regarding the minor and major objective activity markers of IBD and to evaluate the cut-off
correlation between faecal infliximab (IFX) concentration and
and 12. Cut off levels of the preoperative measured
objective activity markers of IBD and to evaluate the cut-off
surgical complications. rmined regarding the minor and major value of faecal drug concentration in the respect of faecal
parameters will be dete
surgical complications. calprotectin in patients treated with maintenance IFX
value of faecal drug concentration in the respect of faecal
calprotectin in patients treated with maintenance IFX
33. BISPHOSPHONATE TREATMENT OF therapy.

therapy.
OSTEOPOROSIS DOES NOT INCREASE THE RISK OF Methods: Consecutive patients with IBD receiving
BISPHOSPHONATE
33.
TREATMENT
OF
st
Methods: Consecutive patients with IBD receiving
OSTEOPOROSIS DOES NOT INCREASE THE RISK OF
SEVERE GASTROINTESTINAL SIDE EFFECTS: A META- maintenance IFX therapy at 1 Dept. of Medicine, University
ANALYSIS OF RANDOMIZED CONTROLLED TRIALS of Szeged were enrolled in the present study. Demographic
st
SEVERE GASTROINTESTINAL SIDE EFFECTS: A META-
maintenance IFX therapy at 1 Dept. of Medicine, University
2
of Szeged were enrolled in the present study. Demographic
2
2
3
ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
1
Dömötör R. , Vörhendi N. , Hanák L. , Hegyi P. , Kiss S. , parameters, data on concomitant medications, C-reactive
parameters, data on concomitant medications, C-reactive
3
2
2
2
2
2
1
Dömötör R. , Vörhendi N. , Hanák L. , Hegyi
2
Csiki E. , Szakó L. , Párniczky A. , Erőss B. P. , Kiss S. , protein (CRP) levels and clinical disease activity indices were
2
Csiki E. , Szakó L. , Párniczky A. , Erőss B.
2
2
1. University of Medicine, Pharmacy, Science and recorded. Faecal samples were obtained before the
protein (CRP) levels and clinical disease activity indices were
2
2
recorded. Faecal samples were obtained before the
1. University of Medicine, Pharmacy, Science and
Technology of Targu Mures; 2. Institute for Translational subsequent IFX infusion. Faecal calprotectin and IFX
subsequent IFX infusion. Faecal calprotectin and IFX
Medicine, University of Pécs Medical School; 3. Doctoral concentrations were determined with ELISA. The
Technology of Targu Mures; 2. Institute for Translational
School of Clinical Medicine, University of Szeged 3. Doctoral correlations of faecal IFX concentration with demographic
Medicine, University of Pécs Medical School;
concentrations were determined with ELISA. The
correlations of faecal IFX concentration with demographic
School of Clinical Medicine, University of Szeged parameters, concomitant steroid and immunomodulator
Introduction: Bisphosphonates (BPs) are first-line therapy therapy, CRP and faecal calprotectin were statistically

parameters, concomitant steroid and immunomodulator
Introduction: Bisphosphonates (BPs) are first-line therapy
therapy,
for severe osteoporosis. BPs-related gastrointestinal (GI) assessed. CRP and faecal calprotectin were statistically
assessed.
for severe osteoporosis. BPs-related gastrointestinal (GI)
adverse events are primarily responsible for low adherence. Results: Eighty-five IBD patients were enrolled.
adverse events are primarily responsible for low adherence.
Results:
patients
IBD
Eighty-five
enrolled.
were
Bisphosphonates appear to be effective, however this topic Female/male ratio was 48.2% - 51.8%. Sixty-five point nine%
Bisphosphonates appear to be effective, however this topic
remained conflicting because of the inconsistent results from of the patients were diagnosed with Crohn’s disease and
Female/male ratio was 48.2% - 51.8%. Sixty-five point nine%
the studies available so far. e of the inconsistent results from 34.1% with ulcerative colitis. Mean disease duration was 14
remained conflicting becaus
of the patients were diagnosed with Crohn’s disease and
the studies available so far.
34.1% with ulcerative colitis. Mean disease duration was 14
Aims: Our meta-analysis aims to objectify the risk of severe years at the time of analysis. Mean duration of IFX therapy
years at the time of analysis. Mean duration of IFX therapy
GI adverse events due to BP therapy in osteoporotic was 39.2 months. Twenty-eight point two% of the patients
Aims: Our meta-analysis aims to objectify the risk of severe
patients. se events due to BP therapy in osteoporotic received escalated IFX therapy. Mean faecal calprotectin
was 39.2 months. Twenty-eight point two% of the patients
GI adver
received escalated IFX therapy. Mean faecal calprotectin
patients.
Methods: A systematic search was conducted in three concentration was 564.9 µg/g. Mean faecal IFX
concentration was 564.9 µg/g. Mean faecal IFX
Methods: A systematic search was conducted in three
databases up to July 2019 for randomized controlled trials concentration was 1 ng/ml. Faecal calprotectin and faecal
(RCTs) detailing gastrointestinal adverse events in adult IFX concentration showed significant correlation (r=0.37,
concentration was 1 ng/ml. Faecal calprotectin and faecal
databases up to July 2019 for randomized controlled trials
(RCTs) detailing gastrointestinal adverse events in adult
patients with osteoporosis on the BP and placebo arms. Risk p=0.002). A cut-off value of faecal IFX level of 0.6 ng/ml was
IFX concentration showed significant correlation (r=0.37,
ratios (RRs) 95% with confidence intervals (CI) were determined at faecal calprotectin concentration of 500 µg/g.
p=0.002). A cut-off value of faecal IFX level of 0.6 ng/ml was
patients with osteoporosis on the BP and placebo arms. Risk
ratios (RRs) 95% with confidence intervals (CI) were
calculated for non-severe and severe adverse events with Further statistical analyses are in progress at the moment.
determined at faecal calprotectin concentration of 500 µg/g.
calculated for non-severe and severe adverse events with
the random-effects model. Statistical heterogeneity was Conclusion: According to our results IFX is detectable in the
Further statistical analyses are in progress at the moment.
Conclusion: According to our results IFX is detectable in the
assessed using chi and I statistics. faeces at a calprotectin concentration of 500 µg/g. The cut-
the random-effects model. Statistical heterogeneity was
2
2
Results: Forty RCTs with 39,047 patients with 9,916 non- off value for faecal IFX concentration proved to be 0.6 ng/ml.
faeces at a calprotectin concentration of 500 µg/g. The cut-
assessed using chi and I statistics.
2
2
off value for faecal IFX concentration proved to be 0.6 ng/ml.
severe and 1,531 severe GI adverse events were included. Simultaneous determination of faecal anti-TNF and faecal
Results: Forty RCTs with 39,047 patients with 9,916 non-
Simultaneous determination of faecal anti-TNF and faecal
There was no difference between BP and placebo groups in calprotectin concentration is supposed to have higher benefit
severe and 1,531 severe GI adverse events were included.
There was no difference between BP and placebo groups in
calprotectin concentration is supposed to hav
terms of the risk of non-severe or severe side effects: in the evaluation of response to IFX therapy. e higher benefit
2
terms of the risk of non-severe or severe side effects:
RR=1.05, (CI: 0.98—1.12), I =46.7%, and RR=1.00 (CI: in the evaluation of response to IFX therapy.
RR=1.05, (CI: 0.98—1.12), I =46.7%, and RR=1.00 (CI:
2

0.90—1.10), I =0.0%, respectively. Subgroup analysis of the 35. GYULLADÁSOS BÉLBETEGSÉG ÉS SPORTOLÁSI
2
2
most commonly used BP, alendronate 70 mg/week, revealed SZOKÁSOK – „PILOT STUDY” EREDMÉNYEK
0.90—1.10), I =0.0%, respectively. Subgroup analysis of the
35. GYULLADÁSOS BÉLBETEGSÉG ÉS SPORTOLÁSI
most commonly used BP, alendronate 70 mg/week, revealed
an increased risk of non-severe GI adverse events [RR=1.18 SZOKÁSOK – „PILOT STUDY” EREDMÉNYEK
an increased risk of non-severe GI adverse events [RR=1.18
45
45

Central European Journal of Gastroenterology and Hepatology 45
Volume 6, Supplementum 2 / November 2020